MX2019012606A - Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr. - Google Patents
Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr.Info
- Publication number
- MX2019012606A MX2019012606A MX2019012606A MX2019012606A MX2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A MX 2019012606 A MX2019012606 A MX 2019012606A
- Authority
- MX
- Mexico
- Prior art keywords
- cd3xegfr
- bispecific antibodies
- seq
- treatment
- egfr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se relaciona a anticuerpos biespecíficos que se unen a CD3 y EGFR simultáneamente. Esta clase de anticuerpo ha demostrado por los inventores ser útil en el tratamiento de tumores EGFR al redirigir las células T y formar una sinapsis inmune entre las células T activadas y EGFR que expresan células tumorales, llevando a mayores niveles de matanza de células tumolares que expresan EGFR. En particular la presente invención se relaciona a anticuerpos biespecíficos de CD3xEGFR_SF4 (SEQ ID NO: 4, 5 y 9), CD3xEGFR_SD1 (SEQ ID NO: 1, 2 y 10) y CD3xEGFR_SD2 (SEQ ID NO: 11, 10 y 2).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17167709 | 2017-04-24 | ||
PCT/EP2018/060488 WO2018197502A1 (en) | 2017-04-24 | 2018-04-24 | T cell redirecting bispecific antibodies for the treatment of egfr positive cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019012606A true MX2019012606A (es) | 2019-12-02 |
Family
ID=58632245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019012606A MX2019012606A (es) | 2017-04-24 | 2018-04-24 | Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230159661A1 (es) |
EP (1) | EP3615571A1 (es) |
JP (1) | JP2020517659A (es) |
KR (1) | KR20200002886A (es) |
CN (1) | CN110831968A (es) |
AU (1) | AU2018259039A1 (es) |
CA (1) | CA3060190A1 (es) |
EA (1) | EA201992143A1 (es) |
MX (1) | MX2019012606A (es) |
SG (2) | SG10201912545PA (es) |
WO (1) | WO2018197502A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230067182A1 (en) * | 2019-11-29 | 2023-03-02 | Boe Technology Group Co., Ltd. | Data Processing Device and Method, and Computer Readable Storage Medium |
EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
WO2022178040A1 (en) * | 2021-02-16 | 2022-08-25 | City Of Hope | Truncated domain iv egfr and uses thereof |
WO2023183766A1 (en) * | 2022-03-20 | 2023-09-28 | Abcellera Biologics Inc. | Anti-cd3 antibodies and t-cell engagers and methods of use |
WO2023192514A1 (en) * | 2022-03-30 | 2023-10-05 | Pinetree Therapeutics, Inc. | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof |
CN114621351B (zh) * | 2022-04-27 | 2023-01-03 | 华羊生物技术股份有限公司 | 多特异性抗体及其治疗癌症的用途 |
WO2024030341A1 (en) * | 2022-07-30 | 2024-02-08 | Pinetree Therapeutics, Inc. | Compositions for targeted lysosomal degradaton and methods of use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101626988B1 (ko) * | 2007-04-03 | 2016-06-02 | 암젠 리서치 (뮌헨) 게엠베하 | 종간 특이적 이중특이적인 결합제들 |
US10329350B2 (en) * | 2012-12-26 | 2019-06-25 | Industrial Technology Research Institute | Method for producing a multivalent fab fragment with collagen-like peptide |
WO2014131711A1 (en) * | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
CA2908988A1 (en) * | 2013-04-19 | 2014-10-23 | Covagen Ag | Novel bispecific binding molecules with antitumoral activity |
CN104341504B (zh) * | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | 双特异性抗体 |
SG10201909806SA (en) * | 2013-11-04 | 2019-11-28 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
CN104774268B (zh) * | 2015-01-21 | 2018-09-28 | 武汉友芝友生物制药有限公司 | 一种双特异性抗体egfr×cd3的构建及应用 |
-
2018
- 2018-04-24 EA EA201992143A patent/EA201992143A1/ru unknown
- 2018-04-24 SG SG10201912545PA patent/SG10201912545PA/en unknown
- 2018-04-24 JP JP2019557468A patent/JP2020517659A/ja active Pending
- 2018-04-24 AU AU2018259039A patent/AU2018259039A1/en not_active Abandoned
- 2018-04-24 EP EP18721725.2A patent/EP3615571A1/en not_active Withdrawn
- 2018-04-24 CA CA3060190A patent/CA3060190A1/en not_active Abandoned
- 2018-04-24 KR KR1020197032632A patent/KR20200002886A/ko unknown
- 2018-04-24 CN CN201880027187.0A patent/CN110831968A/zh active Pending
- 2018-04-24 WO PCT/EP2018/060488 patent/WO2018197502A1/en unknown
- 2018-04-24 SG SG11201909498X patent/SG11201909498XA/en unknown
- 2018-04-24 MX MX2019012606A patent/MX2019012606A/es unknown
- 2018-04-24 US US16/607,783 patent/US20230159661A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN110831968A (zh) | 2020-02-21 |
KR20200002886A (ko) | 2020-01-08 |
WO2018197502A1 (en) | 2018-11-01 |
SG10201912545PA (en) | 2020-02-27 |
EA201992143A1 (ru) | 2020-03-13 |
AU2018259039A1 (en) | 2019-11-07 |
US20230159661A1 (en) | 2023-05-25 |
SG11201909498XA (en) | 2019-11-28 |
EP3615571A1 (en) | 2020-03-04 |
CA3060190A1 (en) | 2018-11-01 |
JP2020517659A (ja) | 2020-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019012606A (es) | Celulas t que redirigen anticuerpos biespecificos para el tratamiento de canceres positivos a egfr. | |
PH12020551211A1 (en) | Antibodies binding to gprc5d | |
PH12019502640A1 (en) | Antibodies specific for flt3 and their uses | |
MX2019010972A (es) | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. | |
MY191649A (en) | Antibodies to tigit | |
MY194642A (en) | Antibodies binding to cd3 | |
PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
UA120060C2 (uk) | Виділене біспецифічне антитіло до cd123 (il3-r-alpha)хcd3 і його застосування | |
MX2022001156A (es) | Anticuerpos que se fijan a gprc5d. | |
NZ760841A (en) | Agonist antibodies that bind human cd137 and uses thereof | |
PH12020551153A1 (en) | Antibodies specific for cd70 and their uses | |
WO2018165062A8 (en) | Anti-c5 antibodies and uses thereof | |
MX2021000708A (es) | Anticuerpos de cadena pesada que se unen al cd19. | |
JOP20190246A1 (ar) | جسم مضاد أحادي النسيلة لـ pd-l1 | |
MX2020012539A (es) | Anticuerpos especificos para cd3 y sus usos. | |
MX2021004454A (es) | Anticuerpos anti-sinucleina. | |
WO2018148486A8 (en) | Anti-factor d antibodies and uses thereof | |
PH12019502274A1 (en) | Antibodies binding to steap-1 | |
MX2021003636A (es) | Receptor antigenico quimerico. | |
WO2019182867A8 (en) | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor | |
MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. | |
MX2021015766A (es) | Nuevos antigenos y metodos contra el cancer. | |
MX2022006145A (es) | Anticuerpos trem2 y usos de estos. |